

AMENDMENT

Claim 7 has been amended as follows:

B
7. (Amended) A method for treating an infection of HCV comprising administering to a patient a therapeutically effective amount of a CD81 protein, or a functional equivalent thereof, to reduce the infectivity of the virus.

Please cancel claims 1-6 and 8-26 without prejudice and without disclaimer and add the following new claims:

--27. (New) The method of claim 7, wherein the functional equivalent has at least 80% sequence identity to the human CD81 amino acid sequence depicted in Figure 1.

Part Cont'd
28. (New) The method of claim 7, wherein the functional equivalent is a soluble form of the CD81 protein.

Sub C3
29. (New) The method of claim 28, wherein the soluble form of the CD81 protein comprises a deletion of one or more of the transmembrane binding domains depicted as TM1, TM2, TM3 and TM4 in Figure 1.

30. (New) The method of claim 29, wherein the soluble form of the CD81 protein comprises amino acids 113-201 of the human CD81 amino acid sequence depicted in Figure 1.

Atty Dkt No. 0366.103
USSN: 09/509,612
PATENT

B2 concld.
Subj3

31. (New) The method of claim 7, wherein the CD81 protein comprises the human CD81 amino acid sequence depicted in Figure 1.--

Attached is a marked-up version of the changes made to the claims and specification by the current amendment. The attached page is captioned "Version with markings to show changes made."